20:01 , Nov 2, 2018 |  BC Week In Review  |  Company News

Takeda proposes divestment of Shire GI candidate, announces loans

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it proposed to the European Commission a potential divestment of Crohn’s disease and ulcerative colitis candidate SHP647 once it completes its acquisition of Shire plc (LSE:SHP; NASDAQ:SHPG). The move...
18:16 , Sep 28, 2018 |  BioCentury  |  Finance

Morphic reloads

With Morphic Therapeutic’s second integrin program running ahead of schedule, the company has raised an $80 million series B round to sustain its current development pace. Existing investor Omega Funds and new investor Novo Holdings...
13:56 , Sep 25, 2018 |  BC Extra  |  Financial News

Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors...
03:14 , Aug 17, 2018 |  BC Week In Review  |  Clinical News

New Phase IIb analyses support further development of Protagonist's UC candidate

Protagonist Therapeutics Inc. (NASDAQ:PTGX) said new analyses from the discontinued Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis showed that the initial findings by an IDMC were "an unfortunate consequence...
17:00 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Takeda's subcutaneous Entyvio meets in Phase III for maintenance therapy of ulcerative colitis

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said subcutaneous Entyvio vedolizumab as maintenance therapy met the primary endpoint vs. placebo in the Phase III VISIBLE 1 trial to treat ulcerative colitis in patients who achieved a clinical...
17:56 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Protagonist discontinues Phase IIb of PTG-100 for UC

Protagonist Therapeutics Inc. (NASDAQ:PTGX) discontinued the Phase IIb PROPEL trial of once-daily PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide whether to start a Phase II/III trial of the candidate...
18:13 , Mar 26, 2018 |  BC Extra  |  Clinical News

Protagonist shares halved on UC failure

Protagonist Therapeutics Inc. (NASDAQ:PTGX) was down $11.68 (57%) to $8.75 on Monday after the company discontinued the Phase IIb PROPEL trial of PTG-100 to treat moderate to severe ulcerative colitis. Protagonist said it will decide...
19:18 , Feb 21, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers The pre-HIV infection fraction of CD4 + T cells expressing integrin α 4 β 7 could help predict susceptibility to HIV infection. In 70 of 206 at-risk women from South Africa and...
22:07 , Dec 1, 2017 |  BC Week In Review  |  Company News

Takeda, Portal partner to develop needle-free biologics

Portal Instruments Inc. (Cambridge, Mass.) partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to develop and commercialize Portal’s needle-free drug delivery device for use with Takeda’s investigational and approved biologics. The device delivers biologics through a...
19:04 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Protagonist raises $60M in follow-on

On Oct. 11, Protagonist Therapeutics Inc. (NASDAQ:PTGX) raised $60 million through the sale of 3.5 million shares at $17 in a follow-on underwritten by Leerink, Barclays, BMO Capital Markets, Stifel, BTIG and Nomura. The price...